1. NOACs and Reversal Agents

3. Program Goals

5. Outcomes of Patients With Major Bleeding Dabigatran vs Warfarin

6. OAC Use in Patients With AF

7. Idarucizumab

8. RE-VERSE AD Idarucizumab Interim Analysis

9. Andexanet Alfa

10. ANNEXA-A and ANNEXA-R Rapid Reversibility of Anti-Factor Xa Activity With Andexanet Alfa

11. ANNEXA-A and ANNEXA-R Rapid Restoration of Thrombin Generation With Andexanet Alfa

12. Ciraparantag/Aripazine

13. Ciraparantag/Aripazine Reversal of Edoxaban Activity

14. Candidates for Reversal Agents

15. ANNEXA-4 Inclusion/Exclusion Criteria

16. Prior to Reversal Factors to Consider

17. Management of Bleeding In the Absence of Reversal Agents

18. Reversal Agents Practical Considerations

19. Summary

20. Abbreviations

21. Abbreviations (cont)